# Relapsed or Refractory Multiple Myeloma FDA approvals and PDUFA dates

Canonical: https://sec-api.dev/indications/relapsed-or-refractory-multiple-myeloma

> 4 upcoming FDA catalysts in relapsed or Refractory Multiple Myeloma: anitocabtagene autoleucel (GILD) on December 23, 2026 (PDUFA date); Pomalyst (pomalidomide, BMY) on Jan to Apr 2027 (topline data readout); Pomalyst (pomalidomide, BMY) on January 2027 (primary completion); mezigdomide (BMY) on May 13, 2027 (PDUFA date).

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: quarter only, month only, exact day.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Verified answer

### What are the upcoming FDA decisions for relapsed or Refractory Multiple Myeloma?

4 upcoming FDA catalysts in relapsed or Refractory Multiple Myeloma: anitocabtagene autoleucel (GILD) on December 23, 2026 (PDUFA date); Pomalyst (pomalidomide, BMY) on Jan to Apr 2027 (topline data readout); Pomalyst (pomalidomide, BMY) on January 2027 (primary completion); mezigdomide (BMY) on May 13, 2027 (PDUFA date). Press release filed with the SEC (EX-99): "•Announced that the Biologics License Application for anito-cel in 4L+ R/R MM has been accepted by FDA, with a PDUFA target action date of December 23, 2026." [Calendar and source filings](https://sec-api.dev/indications/relapsed-or-refractory-multiple-myeloma)

Source: Press release filed with the SEC (EX-99), accession 0000882095-26-000022, https://www.sec.gov/Archives/edgar/data/882095/000088209526000022/exhibit991earningspressrel.htm (retrieved 2026-11-12). Last confirmed 2026-10-30. Cite: https://sec-api.dev/indications/relapsed-or-refractory-multiple-myeloma#answer

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| Sep to Dec 2026 | [Mezigdomide topline data readout](https://sec-api.dev/pdufa/mezigdomide) | BMY | Relapsed or Refractory Multiple Myeloma | scheduled | "NCT05552976 (A Study to Evaluate Mezigdomide in Combination With Carfilzomib and Dexamethasone (MeziKD) Versus Carfilzomib and Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma (SUCCESSOR-2)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-09-28 (ESTIMATED); Lead Sponsor Bristol-Myers Squibb." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05552976)) |
| September 2026 | [Mezigdomide primary completion](https://sec-api.dev/pdufa/mezigdomide) | BMY | Relapsed or Refractory Multiple Myeloma | delayed | "NCT05552976 (A Study to Evaluate Mezigdomide in Combination With Carfilzomib and Dexamethasone (MeziKD) Versus Carfilzomib and Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma (SUCCESSOR-2)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-09-28 (ESTIMATED); Lead Sponsor Bristol-Myers Squibb." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05552976)) |
| December 23, 2026 | [Anitocabtagene autoleucel PDUFA date](https://sec-api.dev/pdufa/anitocabtagene-autoleucel) | GILD | relapsed or refractory multiple myeloma | scheduled | "•Announced that the Biologics License Application for anito-cel in 4L+ R/R MM has been accepted by FDA, with a PDUFA target action date of December 23, 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/882095/000088209526000022/exhibit991earningspressrel.htm)) |
| Jan to Apr 2027 | [Pomalyst (pomalidomide) topline data readout](https://sec-api.dev/pdufa/pomalidomide) | BMY | Relapsed or Refractory Multiple Myeloma | scheduled | "NCT05519085 (A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-01-10 (ESTIMATED); Lead Sponsor Celgene." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05519085)) |
| January 2027 | [Pomalyst (pomalidomide) primary completion](https://sec-api.dev/pdufa/pomalidomide) | BMY | Relapsed or Refractory Multiple Myeloma | scheduled | "NCT05519085 (A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-01-10 (ESTIMATED); Lead Sponsor Celgene." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05519085)) |
| May 13, 2027 | [Mezigdomide PDUFA date](https://sec-api.dev/pdufa/mezigdomide) | BMY | relapsed or refractory multiple myeloma | scheduled | "The FDA accepted a New Drug Application for mezigdomide in combination with carfilzomib and dexamethasone (MeziKd) in patients with relapsed or refractory multiple myeloma (RRMM), granting a PDUFA date of May 13, 2027." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/14272/000001427226000018/a2026q2ex991-filing.htm)) |

## Drugs

- [Mezigdomide](https://sec-api.dev/pdufa/mezigdomide) (BMY)
- [Anitocabtagene autoleucel](https://sec-api.dev/pdufa/anitocabtagene-autoleucel) (GILD)
- [Pomalyst (pomalidomide)](https://sec-api.dev/pdufa/pomalidomide) (BMY)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/indications/relapsed-or-refractory-multiple-myeloma.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Relapsed or Refractory Multiple Myeloma FDA approvals and PDUFA dates." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/indications/relapsed-or-refractory-multiple-myeloma

```bibtex
@misc{secapidev_indications_relapsed_or_refractory_multiple_myeloma_20261116,
  title        = {Relapsed or Refractory Multiple Myeloma FDA approvals and PDUFA dates},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/indications/relapsed-or-refractory-multiple-myeloma}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_indications_relapsed_or_refractory_multiple_myeloma_20261116","title":"Relapsed or Refractory Multiple Myeloma FDA approvals and PDUFA dates","publisher":"sec-api.dev","URL":"https://sec-api.dev/indications/relapsed-or-refractory-multiple-myeloma","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
